All Articles

Do navigated patients use the emergency department differently than patients who do not have a navigator? The authors of this study present their findings.

A keynote highlighting genomic profiling in the management of patients with intrahepatic cholangiocarcinoma.

Collecting metrics may seem like an intimidating endeavor, but navigators report once you start, it's hard to stop!

What you need to know about the CoC and updates to survivorship program standards.

Are you aware of the new screening guidelines?

Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.

Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talqueta­mab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination.

A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk.